<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147832">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01687387</url>
  </required_header>
  <id_info>
    <org_study_id>IPH2102-201</org_study_id>
    <nct_id>NCT01687387</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)</brief_title>
  <acronym>EFFIKIR</acronym>
  <official_title>Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of
      lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients
      with Acute Myeloid Leukemia (AML) in first complete remission
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Leukemia-Free Survival</measure>
    <time_frame>from date of randomization until the date of first documented relapse, assessed up to 48 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>from the time of patient signing the consent form until 28 days after the last administration, or until the patient's last study visit, up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>based on full physical examination each treatment visit and collection of AEs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IPH2102 at 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lirilumab (IPH2102/BMS986015) at 1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPH2102 at 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lirilumab (IPH2102/BMS986015) at 0.1 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal saline solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2102  at 0.1 mg/kg</intervention_name>
    <description>every 3 months</description>
    <arm_group_label>IPH2102 at 0.1 mg/kg</arm_group_label>
    <other_name>lirilumab/BMS986015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPH2102  at 1 mg/kg</intervention_name>
    <description>every 4 weeks</description>
    <arm_group_label>IPH2102 at 1 mg/kg</arm_group_label>
    <other_name>lirilumab/BMS986015</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (normal saline solution)</intervention_name>
    <description>every 4 weeks</description>
    <arm_group_label>IPH2102 at 0.1 mg/kg</arm_group_label>
    <arm_group_label>Placebo (Normal saline solution)</arm_group_label>
    <other_name>normal saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary or secondary Acute Myeloid Leukemia (AML, defined according to WHO 2008
             criteria), in first CR/CRi (according to the revised recommendations of the
             International Working Group for Diagnosis, Standardization of Response Criteria,
             Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid
             Leukemia J Clin Oncol. 2003 Dec 15; 21(24):4642-9 see appendix 19.3) following
             induction chemotherapy and who received 1 or 2 consolidation cycles. Induction
             chemotherapy should be performed within 6 months before randomization. Consolidation
             cycle is defined as any chemotherapy administered within 3 months following CR and
             including aracytine irrespective of the administered dose(s). A minimum of one and
             maximum of 2 cycles should be administered before enrollment

          2. Patients not eligible for an allogeneic  hematopoietic  cell transplantation

          3. Age 60 to 80

          4. ECOG Performance status of 0 or 1

          5. Clinical laboratory values at screening

               -  Calculated creatinine clearance (according to MDRD) &gt; 60 ml/min/1.73 m2

               -  Platelet  &gt; 75 x 109/l

               -  Hemoglobin ≥  10 g/dl supported or unsupported by transfusions

               -  ANC      &gt; 1 x 109/l

               -  Total Bilirubin levels ≤ 1.5 ULN

               -  ALT and AST ≤ 3 ULN

          6. Recovery from acute toxicity of previous anti-tumor therapy

          7. Male patients who accept and are able to use contraception methods recognized as
             highly effective.

          8. Signed informed consent prior to any protocol specific procedure.

        Exclusion Criteria:

          1. Acute Promyelocytic Leukemia with t (15; 17), or its molecular equivalents (PML-RARA)

          2. Favorable risk AML corresponding defined as t(8;21)  or inv (16) and t(16;16) and
             their molecular equivalents (AML-ETO and  CBFB-MYH11)

          3. Last consolidation completed more than 3 months prior to first dosing

          4. Concomitant treatment by chemotherapy, immunotherapy or by systemic corticosteroids

          5. Within 28 days prior to first dosing: chemotherapy or systemic corticosteroid
             treatment

          6. History of allogeneic hematopoietic cell transplantation or solid organ
             transplantation

          7. History of high dose chemotherapy with autologous hematopoietic transplantation
             performed as treatment for AML

          8. Use of any investigational agent within 2 months prior to the first dosing

          9. Use of growth factors (G- or GM-CSF or EPO) within 28 days prior to first dosing

         10. Any irradiation within the last 3 months except for analgesic intent

         11. Intermittent or continuous renal replacement therapy

         12. Abnormal cardiac status with any of the following

               -  Ejection fraction (measured by ultra-sound or radionuclide imaging) &lt;50%

               -  Myocardial infarction within the previous 6 months

               -  QTc ≥ 480 ms (Bazett's).

         13. Current active infectious disease or positive serology for HIV, and/or HCV  with
             detectable viremia and/ or HBV with positive Hbs Antigen and/or negative anti Hbs
             Antibody

         14. Auto-immune disease:

               -  Which currently or previously required systemic immunosuppressive or
                  immuno-modulatory therapy (including corticosteroids administered by systemic
                  route)

               -  And/or has substantial probability to cause an irreversible injury to any tissue

               -  And/or is recent or unstable or has substantial risk to progress and cause
                  severe complications.

         15. Serious concurrent uncontrolled medical disorder

         16. History of another malignancy (apart from myelodysplastic syndromes, basal cell
             carcinoma of the skin, or in situ cervix carcinoma) except if free of disease for ≥ 3
             years

         17. Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes Marseille France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Dombret, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ALFA cooperative Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Ifrah, MD</last_name>
    <role>Study Chair</role>
    <affiliation>GOELAMS Cooperative Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud Buffet, MD</last_name>
    <email>renaud.buffet@innate-pharma.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Zerbib</last_name>
    <email>robert.zerbib@innate-pharma.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Marolleau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathilde Hunault-Berger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent Sutton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de la côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Banos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrice LAROSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abderrazak EL YAMANI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude Gardin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gaëlle Guillerm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHG de Béziers</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain Saad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ioana-Dana Vaida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Militaire Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Valère Malfuson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Romain Guieze</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier sud francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stéphanie Haïat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cécile Pautas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude-Eric Bulabois</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Rousselot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Quesnel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascal Turlure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli - Calmettes</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norbert Vey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jamilé Frayfer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yosr HICHRI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Ojeda-Uribe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques Delaunay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lauris Gastaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Jourdan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magda Alexis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Françoise Isnard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Raffoux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Hermine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint-Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurence Sanhes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud Pigneux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xavier Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Guilhot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédérique ORSINI-PIOCELLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chantal HIMBERLIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane Leprêtre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacques Vargaftig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint-Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Réda Garidi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haute Pierre et Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Lioure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Recher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Fernandes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy Hôpitaux de Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline Bonmati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Henri Bourhis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
